Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A

RT @RPTHjournal: New #RPTH study by Chowdary et al: fixed doses of turoctocog alfa pegol (N8-GP), an extended t1⁄2 recombinant FVIII produc…

RT @RPTHjournal: Prophylaxis w/ fixed doses of the rFVIII product N8-GP may provide adequate coverage for severe #hemophilia A. Read the wo…

RT @RPTHjournal: Prophylaxis w/ fixed doses of the rFVIII product N8-GP may provide adequate coverage for severe #hemophilia A. Read the wo…

Prophylaxis w/ fixed doses of the rFVIII product N8-GP may provide adequate coverage for severe #hemophilia A. Read the work by Chowdary et al. in the #RPTH July print issue, available at the @ISTH booth! 😀 #ISTH2019